IV meloxicam
-
FDA Rejects Malvern-Based Recro Pharma’s Application for Non-Opioid Pain Med
Recro Pharma’s stock took a major hit after the FDA rejected a new drug application for the Malvern company’s non-opioid pain medication, writes John George…
-
Malvern’s Recro Pharma to Use Stock Proceeds on Potential Commercial Launch
Malvern’s Recro Pharma is already preparing for the potential commercial launch of its highly anticipated new drug with a $35.9 million public stock offering, writes…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
